Compare F5 Inc (FFIV) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
F5 Inc vs TG Therapeutics Inc — how do they compare? F5 Inc trades at $402.69 (market cap $23.79B), while TG Therapeutics Inc trades at $54.82 (market cap $8.64B). The key difference: F5 Inc is far larger — about 2.8× TG Therapeutics Inc's market cap. Which is the better fit depends on your goals.
| FFIV | TGTX | |
|---|---|---|
Market Cap | $23.79B | $8.64B |
Sector | Technology | Health |
52-Week High | $431.26 | $59.06 |
52-Week Low | $223.99 | $26.39 |
Enterprise Value | $22.60B | $8.88B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
F5 (FFIV) trades at $403.30, down 6.48% on the day, yet maintains a bullish technical trend with strong fundamental performance. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $3.90 surpassing the $3.46 expectation. Revenue growth is steady, reaching $3.09 billion in 2025, supported by strategic expansions into AI security, including the acquisition of SurePath AI and new platform launches.
The outlook is positive, driven by robust profitability and strategic positioning in application security. However, risks include high valuation multiples and competitive pressures. Analyst consensus is a 'Hold' with a $397 price target, slightly below the current price, indicating cautious optimism amid growth initiatives.
TG Therapeutics (TGTX) trades at $55.19, up 0.55% on the day, with a bullish technical signal from moving averages. The company shows strong profitability with a 65.95% net income margin and 112.6% ROE, though recent quarterly EPS has missed expectations. Positive clinical trial news for Briumvi in multiple sclerosis and schizophrenia is driving investor optimism and media coverage.
The outlook is supported by robust revenue growth and pipeline expansion, but risks include clinical trial execution and recent earnings volatility. Analysts are predominantly bullish with an 84.6% buy rating, though the consensus price target of $48.50 sits below the current price, suggesting potential near-term consolidation.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About F5 Inc
F5 is a market leader in the application delivery controller market. The company sells products for networking traffic, security, and policy management. Its products ensure applications are safely routed in efficient manners within on-premises data centers and across cloud environments. More than half of its revenue is based on providing services, and its three customer verticals are enterprises, service providers, and government entities. The Seattle-based firm was incorporated in 1996 and generates sales globally.
Read more on FFIV →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
